EP2723372A4 - PROTECTION AGAINST DENGUE VIRUS AND PREVENTION OF SEVERE FORMS OF DENGUE - Google Patents

PROTECTION AGAINST DENGUE VIRUS AND PREVENTION OF SEVERE FORMS OF DENGUE

Info

Publication number
EP2723372A4
EP2723372A4 EP12801934.6A EP12801934A EP2723372A4 EP 2723372 A4 EP2723372 A4 EP 2723372A4 EP 12801934 A EP12801934 A EP 12801934A EP 2723372 A4 EP2723372 A4 EP 2723372A4
Authority
EP
European Patent Office
Prior art keywords
dengue
prevention
protection against
severe forms
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12801934.6A
Other languages
German (de)
French (fr)
Other versions
EP2723372A2 (en
Inventor
Sujan Shresta
Lauren Yauch
Alessandro Sette
Daniela Weiskopf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Institute for Allergy and Immunology
Original Assignee
La Jolla Institute for Allergy and Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/041889 external-priority patent/WO2011163628A2/en
Application filed by La Jolla Institute for Allergy and Immunology filed Critical La Jolla Institute for Allergy and Immunology
Publication of EP2723372A2 publication Critical patent/EP2723372A2/en
Publication of EP2723372A4 publication Critical patent/EP2723372A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP12801934.6A 2011-06-24 2012-06-25 PROTECTION AGAINST DENGUE VIRUS AND PREVENTION OF SEVERE FORMS OF DENGUE Withdrawn EP2723372A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2011/041889 WO2011163628A2 (en) 2010-06-24 2011-06-24 Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof
PCT/US2012/044071 WO2012178196A2 (en) 2011-06-24 2012-06-25 Protection against dengue virus and prevention of severe dengue disease

Publications (2)

Publication Number Publication Date
EP2723372A2 EP2723372A2 (en) 2014-04-30
EP2723372A4 true EP2723372A4 (en) 2015-03-04

Family

ID=47424845

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12801934.6A Withdrawn EP2723372A4 (en) 2011-06-24 2012-06-25 PROTECTION AGAINST DENGUE VIRUS AND PREVENTION OF SEVERE FORMS OF DENGUE

Country Status (2)

Country Link
EP (1) EP2723372A4 (en)
WO (1) WO2012178196A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2986071B1 (en) * 2012-01-24 2014-02-28 Biomerieux Sa METHOD FOR PROGNOSING, IN VITRO, IN A BLOOD SAMPLE, THE PROBABILITY FOR A PATIENT TO EVOLVE TO A SEVERE DENGUE
EP2959915A1 (en) * 2014-06-23 2015-12-30 Institut Pasteur A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
CN115804362A (en) * 2023-02-08 2023-03-17 中国医学科学院医学生物学研究所 IFN-alpha/beta R -/- Injection for enhancing infection of mice by antibody dependency and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944038A1 (en) * 2005-09-16 2008-07-16 Centro De Ingenieria Genetica Y Biotecnologia (Cigb) Dengue virus capsid protein which induces a protective response and pharmaceutical composition
WO2009152147A2 (en) * 2008-06-09 2009-12-17 La Jolla Institute For Allergy And Immunology Compositions and methods for dengue virus (dv) treatment and vaccination
WO2011163628A2 (en) * 2010-06-24 2011-12-29 La Jolla Institute For Allergy And Immunology Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7476390B2 (en) * 2002-02-26 2009-01-13 Maxygen, Inc. Flavivirus antigens
GB0620894D0 (en) * 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944038A1 (en) * 2005-09-16 2008-07-16 Centro De Ingenieria Genetica Y Biotecnologia (Cigb) Dengue virus capsid protein which induces a protective response and pharmaceutical composition
WO2009152147A2 (en) * 2008-06-09 2009-12-17 La Jolla Institute For Allergy And Immunology Compositions and methods for dengue virus (dv) treatment and vaccination
WO2011163628A2 (en) * 2010-06-24 2011-12-29 La Jolla Institute For Allergy And Immunology Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D. WEISKOPF ET AL: "Insights into HLA-Restricted T Cell Responses in a Novel Mouse Model of Dengue Virus Infection Point toward New Implications for Vaccine Design", THE JOURNAL OF IMMUNOLOGY, vol. 187, no. 8, 14 September 2011 (2011-09-14), pages 4268 - 4279, XP055009133, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1101970 *
GUNTHER V J ET AL: "A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness", VACCINE, ELSEVIER LTD, GB, vol. 29, no. 22, 11 March 2011 (2011-03-11), pages 3895 - 3904, XP028204255, ISSN: 0264-410X, [retrieved on 20110317], DOI: 10.1016/J.VACCINE.2011.03.038 *
L. E. YAUCH ET AL: "A Protective Role for Dengue Virus-Specific CD8+ T Cells", THE JOURNAL OF IMMUNOLOGY, vol. 182, no. 8, 15 April 2009 (2009-04-15), pages 4865 - 4873, XP055009120, ISSN: 0022-1767, DOI: 10.4049/jimmunol.0801974 *
L. E. YAUCH ET AL: "CD4+ T Cells Are Not Required for the Induction of Dengue Virus-Specific CD8+ T Cell or Antibody Responses but Contribute to Protection after Vaccination", THE JOURNAL OF IMMUNOLOGY, vol. 185, no. 9, 24 September 2010 (2010-09-24), pages 5405 - 5416, XP055161290, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1001709 *

Also Published As

Publication number Publication date
WO2012178196A2 (en) 2012-12-27
EP2723372A2 (en) 2014-04-30
WO2012178196A3 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
IL216605A0 (en) Treatment and prevention of dengue virus infections
IL262734B (en) Influenza virus inhibitor compounds and uses thereof
AP3576A (en) Inhibitors of flaviviridae viruses
EP2400845A4 (en) Thienopyridine derivatives for the treatment and prevention of dengue virus infections
AP3409A (en) Inhibitors of flaviviridae viruses
EP2707025A4 (en) IMMUNOGENIC COMPOSITIONS AGAINST GLYCOPROTEIN G FROM HENDRA AND NIPAH VIRUSES
AP2012006413A0 (en) Inhibitors of flaviviridae viruses
BR112012020724A2 (en) debris protection and protected geocontainer
BR112013015771A2 (en) cyclosporine derivatives for the treatment and prevention of a viral infection
DK2470191T3 (en) Methods and preparations for the prevention or treatment of ophthalmic conditions
ITTO20110641A1 (en) PHARMACEUTICAL COMPOSITIONS AND TREATMENT METHODS
BR112012005438A2 (en) flaviviridae virus inhibitors
SG11201500439RA (en) Vaccine compositions for prevention against dengue virus infection
BR112014013221A2 (en) protection of entries against malware
EP2672970A4 (en) FORMS OF RIFAXIMINE AND USES THEREOF
EP2928470A4 (en) Thienopyridine derivatives for the treatment and prevention of dengue virus infections
BRPI0811870A2 (en) INFLUENCE TREATMENT AND PREVENTION
IL243204A0 (en) Compositions and methods for administration of vaccines against dengue virus
EP2646052A4 (en) FORMULATIONS OF LYOPHILIZED VIRUSES
EP2563121A4 (en) METHODS AND COMPOSITIONS FOR PROTECTION AGAINST NEUROTOXIC AGENTS
EP2754079A4 (en) SCANNER OF PROTECTION AGAINST THE RISKS OF MALICIOUS SOFTWARE
EP2678043A4 (en) RECOMBINANT VACCINE AGAINST MURDER VIRUS
BR112013014915A2 (en) curative composition and treatment methods
EP2723372A4 (en) PROTECTION AGAINST DENGUE VIRUS AND PREVENTION OF SEVERE FORMS OF DENGUE
ZA201307019B (en) Compositions for preventing and/or treating and infection by an hiv-1 virus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140123

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20150202

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/12 20060101AFI20150127BHEP

Ipc: A61K 39/00 20060101ALI20150127BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150902